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Gastric cancer still represents a major health problem, despite a decrease in its incidence in the last years. Due to the social impact
of gastric cancer (GC), there is a need for novel biomarkers in order to stratify patients into appropriate screening, surveillance, or
treatment programs. Although histopathology remains the most reliable and less expensive method, numerous efforts have been
made searching for novel biomarkers. In recent years, several molecules have been identified and tested for their clinical relevance
in GC management. In this paper, we will focus on a well-known GC marker, whose determination is mandatory in GC, HER2,
a marker whose correlation with prognosis is still controversial (VEGF-A) and a quite novel, unconventional marker, the ether-a`-
go-go-related gene 1 (hERG1). All these proteins can be easily detected with immunohistochemistry, a technique widely used both
in diagnostic and research laboratories that represents a link between surgical and molecular pathology, basic science, and clinical
medicine.
1. Gastric Cancer
Gastric cancer (GC) still represents a major health problem,
despite a decrease in its incidence in the last years [1].
According to the most recent estimates, GC accounts for
8% of the total cancer cases and for 10% of the deaths for
all cancers [2]. GC is characterized by a clear geographical
distribution, with over 70% of the cases occurring in
developing countries. This is partly due to dietary habits
as well as Helicobacter pylori infection prevalence. Indeed,
the reasons accounting for the decreased GC incidence in
most countries are related to changes in dietary habits,
amelioration of food preservation, reduction in H. pylori
chronic infection [3–5] as well as reduction in smoking [1].
The majority of stomach tumors are sporadic, while
only a small percentage have a familial component, with
an autosomal pattern of inheritance. GC is a multifactorial
disease characterized by both genetic and environmental
components. In sporadic cancers of the stomach, the envi-
ronmental component seems to be predominant. Conversely,
the genetic component plays a major role in familial cancers.
About 90% of GCs are classified as adenocarcinomas, whilst
the remaining 10% is represented by non-Hodgkin lym-
phomas, leiomyosarcomas, squamous cell carcinomas, and
undifferentiated carcinomas. In this paper, we will mainly
refer to adenocarcinomas, addressing them as simply “GCs.”
According to the Lauren’s classification, two subtypes of GC
can be distinguished basing on their different histology: the
intestinal (I-GC) and diffuse (D-GC) types [6]. The two
GC types also display different biological and etiological
characteristics. Tumor cells of I-GC form glandular-like
structures, a feature which lacks in D-GC, which, on the
contrary, is characterized by the infiltration and thickening
of the gastric wall by tumor cells. The two histological
subtypes are the result of distinct pathogenetic pathways,
well described in the two models, proposed to depict the
pathogenesis of I-GC [7] and D-GC [8]. As shown in
Figure 1, I-GC occurrence is preceded by the development of
chronic gastritis, which in turn leads to atrophy, and by the
subsequent appearance of intestinal metaplasia. Intestinal
metaplasia arises from the proliferation of gastric stem
cells, whose progeny differentiates into “intestinal type” cells
(columnar, goblet, and Paneth cells), due to the persistent
irritation of the gastric mucosa, caused by H. pylori [9].
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Figure 1: Correa model for intestinal type GC.
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Figure 2: Carneiro’s model for diffuse type GC.
The Correa model is not applicable to the pathogenesis of
D-GC. The latter is, however, well described by the Carneiro
model [8] (Figure 2).
The diffuse type GC is characterized by reduced or
abnormal E-cadherin expression [10, 11]. The inactivation
of the second CDH1 allele (e.g., the gene encoding E-
cadherin) leads to the appearance of an in situ carcinoma,
with the presence of signet-ring cells with a “Pagetoid”
pattern of diffusion, which is subsequently followed by
the invasion of surrounding tissues. According to this
model, the intraepithelial presence of signet-ring cells does
not represent a secondary colonization. On the whole, E-
cadherin loss/abnormality represents an early event in the
cancerogenesis of D-GC [8], and the dysregulation of the
gene is one of the most frequent genetic alterations in diffuse
type GC [12].
Due to the social impact of GC, there is a need to
stratify patients into appropriate screening, surveillance, or
treatment programs. Although histopathology remains the
most reliable and less expensive method, numerous efforts
have been made to identify and validate novel biomarkers to
accomplish the above goals. In recent years, several molecules
have been identified and tested for their clinical relevance in
GC management. Table 1 shows an overview of some of the
biomarkers reported so far, along with the most correlated
clinical parameters. With the exception of HER2, none of the
biomarkers reported in the table is currently used in clinical
practice, and some of them were described in single studies.
Immunohistochemistry (IHC) staining of formalin-fixed
and paraffin-embedded tissues is widely used in diagnostic
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Figure 3: HER family receptors.
surgical pathology to gather additional information embrac-
ing those obtained with classical hematoxylin and eosin
staining. IHC assists the pathologists in areas of tumor clas-
sification, multilineage differentiation, molecular correlates,
and infectious etiologies. Moreover, IHC is commonly used
to detect markers, which in turn can provide information on
the biological behaviour and prognosis of a tumor. Different
biomarkers detected by IHC are now a common component
for many institutional review board protocols, for a more
precise risk stratification and target identification. Therefore,
IHC represents a link between surgical and molecular
pathology, basic science and clinical medicine, surgery, and
radiology [13].
As evidenced in Table 1, the number of potential
biomarkers in GC is quite high and still increasing. Those
which are easily detectable and quantifiable through IHCwill
be the object of the present review. In particular, we will focus
on HER2, a well-known GC marker, whose determination
is mandatory in GC, a marker whose correlation with
prognosis is still controversial, VEGFs and quite novel,
unconventional marker, hERG1.
1.1. HER2. The HER family comprises four different recep-
tors: HER1 (EGFR or ErbB1), HER2 (ErbB2 or HER-2/Neu),
HER3 (ErbB3), and HER4 (ErbB4) (Figure 3).
These receptors cooperate in the regulation of different
processes, such as cell proliferation, differentiation, and
International Journal of Surgical Oncology 3
survival [14]. HER family members are implicated in the
development of different kinds of tumors and are now
recognized targets for biological therapy in breast, colorectal,
lung, head and neck, gastric and gastro-oesophageal junc-
tion cancer (reviewed in [15]). Upon ligand binding, the
receptors dimerize, become phosphorylated, and transduce
intracellular signals, that ultimately regulate the above-
mentioned cellular processes. Receptor dimerization can
also occur through the process of receptor pairing, other
than ligand binding [16]. Indeed, HER receptors can either
homo- or hetero-dimerize with other HER family members,
allowing multiple receptor combinations [16, 17].
Dimer formation leads to the phosphorylation of key
intracellular proteins, that provide docking sites for a variety
of subsiding signalling molecules. The latter then transmit
signals to different downstream cascades, including the
MAPK and the PI3K/AKT pathways [16, 18].
The HER2 gene has been recognized as a key regulator in
the development of different types of tumors in particular
breast cancer [60]. In GC, HER2 acts as an oncogene,
since gene amplification reflects in protein overexpression,
therefore giving selective advantage tomalignant cells. In GC,
HER2 overexpression has been correlated with poor outcome
and a more aggressive disease [20] as well as with shorter
survival [19–22, 61–65]. Based on data presented at the
ASCOmeeting in 2009, about 22% of patients with advanced
GC have tumors which overexpress HER2. In a large
multicentric trial carried out on GC patients (ToGA study),
a survival benefit of trastuzumab (herceptin) treatment in
HER2-positive patients (IHC score 3+) has been shown
[23]. Therefore, HER2 represents a promising therapeutic
target. However the optimal HER2 testing strategy has not
been defined yet. Due to the recent approval of trastuzumab
for HER2-positive GC in Europe, HER2 diagnostics is
now mandatory: IHC is used as primary test, and it is
followed by fluorescence in situ hybridization (FISH) in
IHC2+ cases [27]. A more recent paper [26] showed that
HER2 amplification can be detected in the two components
(intestinal type and diffuse type areas of the neoplastic
lesion) of Lauren mixed-type tumors. Standardization of
HER2 testing procedures and interpretation is, therefore, an
essential step to ensure accurate and reproducible results.
This point acquires even more relevance, since it has been
shown that HER2 status determination through the same
protocol used for breast cancer, might lead to significant
loss of patients [66] as there are important and significant
differences in HER2 status determination between the two
types of cancer (Table 2, see also [67]). As reported in Table 2,
samples are given a score according to the intensity, degree of
membrane reactivity and the percentage of immunoreactive
cells. Scores 0 and 1+ are considered as negative, score 3+
is considered as positive, while 2+ samples are considered
as equivocal and should be retested by fluorescence in situ
hybridization (FISH) and chromogenic in situ hybridization
(CISH).
If FISH is used as first screening step, only few IHC3+
cases may be missed but it might be found a high percentage
of nonresponders according to ToGA results [24, 68]. In
a more recent study published in 2011 [69] it was shown
Table 1: Immunohistochemical markers in GC.
IHC marker Parameter Reference
HER2
Prognosis [19–23]
Therapeutic response [24]
Lymph node metastasis [25]
Lauren histotype [26, 27]
VEGF
Prognosis [28–31]
Lauren histotype [32]
Tumor progression [33]
Therapeutic response [34]
hERG1 Prognosis [35]
KLF5
Grading [36]
Stage [36, 37]
Lymph node status [36, 37]
Prognosis [36, 37]
CA IX
Lymph node metastasis [38]
Prognosis [38]
Ki67 Lymph node metastasis [25]
PKP3
Stage [39]
Prognosis [39]
MMP-2 Prognosis [29, 31]
HDAC Prognosis [40–42]
Bcl-2 Lymph node metastasis [25]
Bcl-6 Prognosis [43]
SATB1
Lymph node metastasis [44, 45]
Distant metastasis [44, 45]
Stage [44, 45]
c-myc2 Lymph node metastasis [25]
TGF β Stage [46]
E-cadherin
Prognosis [31, 47–52]
Invasion [53]
Grading [54, 55]
Lauren histotype [54]
COX-2 Prognosis [56]
TSP-1 Prognosis [57]
Bax Prognosis [58, 59]
that HER2 testing in GC could be performed using standard
breast cancer procedures and the American Society of
Clinical Oncology/College of American Pathologists scoring
criteria, while a group from Korea concluded that a GC-
specific scoring system should be used [70].
In contrast to HER2 and despite supportive preclinical
data, observed clinical success with anti-HER1 inhibitors
and endocrine therapy combinations in breast cancer has
been limited [71, 72]. In addition to HER1 and HER2,
there is growing interest in HER3 as a potential therapeutic
target [73]. Recently, HER3 and its physiologic ligand
heregulin (HRG) have been implicated in the development
of resistance to antiestrogen therapies in breast carcinoma
[74]. Similarly, the dual HER1 and HER2 TKI lapatinib has
clinical activity and is approved for the therapy of patients
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Table 2: HER2 testing by immunohistochemistry in gastric cancer.
IHC parameters for HER2 testing
protocol
IHC score Classification
Intensity of reactivity
Absent 0 Negative
Faint 1+ Negative
Weak to moderate 2+ Equivocal∗
Moderate to strong 3+ Positive
Degree of membrane reactivity
Complete
2+ Equivocal∗
3+ Positive
Incomplete
0 Negative
1+ Negative
Percentage of immunoreactive cells
(membrane reactivity)
≥10%
1+ Negative
2+ Equivocal∗
3+ Positive
<10% 0 Negative
∗
Samples scored IHC 2+ should be retested with fluorescence in situ
hybridization (FISH) or chromogenic in situ hybridization (CISH).
whose disease has progressed on trastuzumab [74]. Per-
tuzumab is a recombinant humanized monoclonal antibody
directed against the dimerization domain II of HER2 that is
required for ligand-dependent dimerization with HER3 [74].
While trastuzumab prevents ligand-independent HER2 sig-
naling, pertuzumab interferes with ligand-dependent HER3-
mediated signaling.
1.2. VEGF. The vascular endothelial growth factor (VEGF)
family is a multifunctional growth factors’ family, involved in
processes such as angiogenesis, inflammation, and vascular
regeneration. The family includes different members: VEGF-
A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PlGF, charac-
terized by the different ability to bind to three main receptors
Flt1, KDR, and Flt4 (Figure 4).
It has long been known that VEGF-A is the key regulator
of tumor angiogenesis [75], a complex process with a clear
relevance to tumor progression and metastasis. The maxi-
mum diameter a tumor can reach without developing a new
vascular network is about 1-2mm. Hypoxia within tumor
mass induces VEGF-A secretion and increased VEGFR-2
expression [76].
It has been demonstrated that VEGF-A expression is
higher in I-GC compared to D-GC [32]. The expres-
sion of VEGF-C, whose main role is that of promoting
lymphangiogenesis, is related to lymph node metastasis
in GC [77]. VEGF expression is mirrored by microvessel
density (MVD), and they are both hallmarks of enhanced
angiogenesis within the tumor mass and are therefore useful
tools for GC management [78]. MVD has been investigated
as a promoting factor for angiogenesis with conflicting
results about its relation to survival in GC. VEGF secretion
promotes endothelial cell proliferation and therefore the
establishment of a new vascular network. The evaluation of
MVD reflects this latter process since it is evaluated by IHC
with anti-CD34 or anti-CD31 antibodies which specifically
indicate new formed vessels. MVD was significantly related
to the T stage, as to the TNM classification, while VEGF-
C expression was significantly higher in N-positive patients
[79]. No relation was found between MVD and VEGF-C
expression, but VEGF-C and MVD turned out to be related
to clinicopathological features [79].
Although the VEGF superfamily has been identified to
critically influence tumor-related angiogenesis, the prognos-
tic significance of VEGF expression in GC is still contro-
versial. In particular, VEGF-A expression seems to be a
negative prognostic factor, at least in EGCs [80]. Moreover,
VEGF-A expression has been proven to be relevant to
therapeutic response in GC patients treated with fluorouracil
alone or together with cisplatin [81]. We contributed to
this discussion showing that the IHC expression of VEGF-
A, which positively correlated with the Lauren’s intestinal
histotype, has a positive impact on overall survival in
univariate analysis (manuscript in preparation). The reasons
of the different conclusions drawn by several groupsmight be
related to the design of the study and sample characteristics
as well as geographical differences, keeping in mind that GC
is a complex disease with striking differences in different
countries. Furthermore, a recent paper [33], in which
the impact of VEGF-A/C/D on tumor dissemination and
survival in GC was evaluated, led to conclude that VEGF-D,
being associated with progressive disease, could be a helpful
marker of disseminated disease. The authors concluded that
the targeting of VEGF-D might be therefore a potential
therapeutic strategy.
Besides controversies in the interpretation of IHC data,
the Avastin in Gastric Cancer (AVAGAST) trial started in
2007. It was a multinational, randomized, and placebo-
controlled trial aimed to evaluate the efficacy of adding
bevacizumab to capecitabine-cisplatin in the first-line treat-
ment of advanced gastric cancer. Although AVAGAST did
not reach its primary objective, adding bevacizumab to
chemotherapy was associated with significant increases in
progression-free survival and overall response rate in the
first-line treatment of advanced gastric cancer [34].
1.3. hERG1. The human ether-a`-go-go-related gene 1
(hERG1) encodes for a protein, hERG1, which is functionally
a voltage-dependent potassium channel (KV), with outward
rectifying characteristics. hERG1 has the typical structure
of KVs: it is composed of four subunits, each of which
formed by six transmembrane segments (S1–S6), which are
assembled to form a tetramer surrounding a central aqueous
pore. The S4 segment of each subunit is composed of basic
aminoacids (Lys and Arg) and represents the voltage sensor
[82] (Figure 5).
hERG1 constitutes the molecular basis of the cardiac
rapid repolarizing current (IKr) (reviewed in [83]) and
is therefore physiologically relevant to regulate the cardiac
action potential [83]. In addition, hERG1 was found to be
over- and mis-expressed in a wide variety of human cancers
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Figure 4: VEGF receptors and their ligands.
[84–93], where its activity is relevant to drive tumor progres-
sion. In particular, hERG1 activity is modulated by hypoxia
[94] and regulates VEGF-A secretion in astrocytomas [84]. In
addition, hERG1 channels mediate VEGF-Receptor-1 (FLT-
1)-induced cell migration and signalling in acute myeloid
leukemias [90]. hERG1 is also overexpressed in cancers of
the gastrointestinal tract, in particular in colorectal [91, 92]
and oesophageal adenocarcinomas [93]. In colorectal cancer,
it has been recently demonstrated that the IHC positivity to
hERG1, in conjunction to lack of expression of the glucose
transporter 1 (Glut-1) is an independent negative prognostic
factor in TNM stages I and II colorectal cancers [91].
A few papers addressing the expression and role of
hERG1 in GC have been published so far. hERG1 channels
are expressed in GC cell lines, where their activity regulates
cell proliferation in vitro [95, 96]. Shao and colleagues
[95] demonstrated that cisapride, a specific blocker of
hERG1, can inhibit the growth of GC cells, by altering cell
distribution within the cell cycle and inducing apoptosis. A
more recent paper by the same group [97] demonstrated the
correlation between hERG1 expression and tumor grading
and TNM stage. Furthermore, inhibition of the channel with
specific siRNAs resulted in a reduction of tumor growth and
colony formation. Based on these results, hERG1 protein
could be considered as a potential therapeutic target. More
recently, Ding and colleagues [35] demonstrated significant
differences in hERG1 protein expression, according to factors
such as serosal invasion, venous invasion, and TNM stage.
The mean survival time for hERG1 positive patients was
significantly shorter than that of hERG1 negative ones
and hERG1 expression was proven to be an independent
prognostic factor [35]. To our knowledge, these are the
only available data concerning hERG1 in GC addressing
hERG1 as a negative prognostic factor. On the contrary when
performing a study in a larger cohort of 524 GC patients
(manuscript in preparation) encompassing different stages of
the disease, we obtained different conclusions. In particular,
our data confirmed that hERG1 is an independent prognostic
S1 S2 S3 S5S4
cNBD
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S6
+
+
+
Pore
Figure 5: hERG1 potassium channel structure; PAS: Per Arnt Sim
domain, cNBD: cyclic nucleotide-binding domain.
factor, but we demonstrated its association with positive
prognosis.
2. Concluding Remarks
Histopathology still represents the most powerful tool for
gastric cancer management and, in recent years, novel
biomarkers have been identified and tested for their cor-
relations with clinical parameters as well as prognosis. In
the near future new markers will be certainly validated,
and the use of genomics and proteomics might help greatly
clinicians in cancer management. Anyway, the possibility
of validating potential tumor markers using IHC has clear
advantages as it is easy and cost effective and virtually every
pathology laboratory could perform it. Taking into account
the importance and the usefulness of IHC markers, it will be
of great importance in the next future to keep on searching
for novel biomarkers as well as validating those already
identified.
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